Juvederm Voluma — Vycross HA Filler for Cheek Augmentation (FDA Approved)

Juvederm Voluma (VYC-20L) is Allergan’s Vycross-technology cheek volumiser — 20 mg/mL cross-linked HA + 0.3% lidocaine with high G’ translating into lift capacity. FDA approved for cheek and chin augmentation. Engineered for deep subcutaneous and supraperiosteal placement with up to 18 months durability — the longest in the standard Vycross range.

Juvederm Voluma with Lidocaine is manufactured by Allergan / AbbVie, a France-based medical device and pharmaceutical company established in 1948. The product is part of the Juvederm dermal filler range, which is distributed across multiple international markets. Regulatory status: CE 0459 · FDA approved · Manufactured in France.

Juvederm Voluma with Lidocaine contains 20 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Allergan / AbbVie’s Patented Vycross Cross-Linking Technology (VYC-20L) technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Allergan / AbbVie’s clinical data, Juvederm Voluma with Lidocaine delivers Up to 18 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Deep subcutaneous placement typically delivers the longer end of the duration range.

Juvederm Voluma with Lidocaine is engineered for deep subcutaneous · supraperiosteal placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Juvederm Voluma with Lidocaine regulatory status: CE 0459 · FDA approved · Manufactured in France. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Juvederm Voluma with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Juvederm Voluma with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Juvederm Voluma with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Yes — Juvederm Voluma and Juvederm Voluma XC are the same product (VYC-20L) under different regional names. Voluma is the EU/global trade name; Voluma XC is the US FDA-cleared name (where ‘XC’ denotes the lidocaine-containing version). Both share identical Vycross technology, 20 mg/mL HA + 0.3% lidocaine formulation, 2 x 1 mL packaging, and up to 18-month durability. The product was first FDA approved in 2013 for cheek augmentation, making it one of the longest-established Vycross fillers in the global market.